REFERENCES
- Perry M. C. The Chemotherapy Source Book, 2nd ed. Williams & Wilkins, Baltimore 1996
- Ellerhorst J. A., Bedikian A., Ring S., et al. Phase II trial of doxil for patients with metastatic melanoma refractory to front line therapy. Oncol Rep. 1999; 6(5)1097–1099, [INFOTRIEVE], [CSA]
- Comandone A., Bretti S., LaGrotta G., et al. Palmar-plantar erythrodysesthesia syndrome associated with 5-fluorouracil treatment. Anticancer Res. 1993; 13: 1781–1783, [INFOTRIEVE], [CSA]
- Samuels B. L., Vogelzang N. J., Ruane M., et al. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep. 1987; 71(10)971–972, [INFOTRIEVE], [CSA]
- Zimmerman G. C., Keeling J. H., Burris H. A., et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch. Dermatol. 1995; 131(2)202–206, [INFOTRIEVE], [CSA], [CROSSREF]
- Cordonnier C., Roujeau J. C., Vernant J. P., et al. Cancer chepotherapy and erythema. Ann. Intern. Med. 1982; 97: 783, [CSA]
- Chiara S., Nobile M. T., Barzacchi C., et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur. J. Cancer 1997; 33(6)967–699, [INFOTRIEVE], [CSA], [CROSSREF]
- Popescu R. A., Norman A., Ross P. J., et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. 1999; 17(8)2412–2418, [INFOTRIEVE], [CSA]
- Nagore E., Insa A., Sanmartin O., et al. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am. J. Dermatol. 2000; 1(4)225–234, [CSA], [CROSSREF]
- Calista D., Landi C. Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis?. J. Eur. Acad. Dermatol. Venereol. May, 1998; 10(3)274–275, [INFOTRIEVE], [CSA], [CROSSREF]
- Muggia F. M., Hainsworth J. D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractarory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997; 15(3)987–993, [INFOTRIEVE], [CSA]
- Uziely B., Jeffers S., Isacson R., et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995; 13(7)1777–1785, [INFOTRIEVE], [CSA]
- Vail D. M., Chun R, Thamm D. H., et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin. Cancer Res. 1998; 4(6)1567–1571, [INFOTRIEVE], [CSA]
- Fernandez-Galar M., Espana A., Lopez-Picazo J. M., et al. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin. Exp. Dermatol. 2004; 29(2)138–140, [INFOTRIEVE], [CSA], [CROSSREF]
- Jacot W., Bessis D., Jorda E., et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br. J. Dermatol. 2004; 151(1)238–241, [INFOTRIEVE], [CSA], [CROSSREF]
- Kurokawa I., Endo K., Hirabayashi M., et al. Purpuric drug eruption possibly due to gefinitib (Iressa). Int. J. Dermatol. 2005; 44(2)167–168, [INFOTRIEVE], [CSA], [CROSSREF]
- Hui Y. F., Giles F. J., Cortes J. E. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome-recall following different chemotherapy agents. Invest. New Drugs 2002; 20(1)49–53, [INFOTRIEVE], [CSA], [CROSSREF]
- Janinis J., Stathopoulos G. P., Nikolaidis P., Kalofonos H. P., Kalogera-Fountzila A., et al. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Drugs 2004; 15: 479–487, [INFOTRIEVE], [CSA], [CROSSREF]
- Robert C., Soria J. C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet 2005; 6, [CSA]
- Kris M. G., Natale R. B., Herbst R. S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. J. Am. Med. Ass. 2003; 290: 2149–2158, [CSA], [CROSSREF]
- Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003; 21(12), [CSA], [CROSSREF]
- Kris G. M., Natal R. B., Herbst R. S., et al. Efficacy of gefitinib, an inhibitor of the epidemical growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. 2003; 290(16), [CSA]